Please login to the form below

Not currently logged in

Sanofi trumpets new IGlarLixi data after regulatory delay

Reports that the combination drug is more effective at controlling glucose than Lantus alone

Sanofi is highlighting new data for its IGlarLixi combination drug for diabetes showing it is more effective at controlling mealtime blood glucose than its Lantus blockbuster.

The French pharma group has reported a new analysis of phase III results showing that IGlarLixi - which combines the active ingredients in Lantus (insulin glargine) with Sanofi's GLP-1 agonist Lyxumia (lixisenatide) - helped more patients with type 2 diabetes reach post-prandial glucose targets than Lantus.

"Controlling mealtime blood sugar is an important element of maintaining overall blood sugar control, which plays a role in helping patients treat their diabetes," commented Josep Vidal of the Hospital Clinic of Barcelona, who presented the results at the European Association for the Study of Diabetes (EASD) meeting in Munich yesterday.

Prior results from the LixiLan-L trial have shown that the combination is more effective than Lantus in controlling haemoglobin A1c levels, a biomarker for glucose control over time.

Traditionally, the primary goal of blood sugar (glycaemic) control in the treatment of diabetes was to normalise fasting plasma glucose levels. However in recent years it has become established that postprandial plasma glucose levels also play an important role in overall glycaemic control.

Sharp increases in blood glucose after meals can contribute to insulin resistance, decrease insulin production and according to some studies increase the risk of vascular complications.

The data is a minor boost for Sanofi, which is playing catch-up in a race to market with diabetes rival Novo Nordisk to bring a combined insulin/GLP-1 agonist product to the US market.

Novo Nordisk's IDeglira/Xultophy (insulin degludec/liraglutide) is already on the market in Europe, but Sanofi had been hoping to get IGlarLixi to market in the US first with the help of a priority review voucher it bought for $245m.

The FDA scuppered those plans last month by announcing a delay of up to three months in its review of IGlarLixi, setting a decision date to the end of November. Novo Nordisk is due to hear a verdict on Xultophy later this month.

Article by
Phil Taylor

14th September 2016

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...